Skip to content

Alpha Cognition ACOG License — Revenue

Other product segments

Product Net
$3.5M+910%

Similar metrics at other companies

Stoke Therapeutics, Inc. logo
STOKLicense — Revenue
$2.88M-60.9%
MeiraGTx Holdings plc logo
MGTXLicense — Revenue
$18.75M
WEY
WEYSLicense — Revenue
$886K-10.3%
Viridian Therapeutics, Inc. logo
VRDNLicense — Total revenues
$6K
ACI Worldwide logo
ACIWLicense — Revenue
$88.04M+4.2%
Rhythm Pharmaceuticals, Inc. logo
RYTMLicense revenue — Total revenues
$0+100%

Other financials

Income statement

See full
Revenue$3.5M+20.7%
Gross profit$3.3M+12.7%
Operating income-$8.1M-138%
Net income-$6.5M-276%
EPS (diluted)-$0.32-191%

Balance sheet

See full
Cash & equivalents$54.3M+100,638%
Total equity$57.5M+49.2%
Total assets$69.2M+42.5%

Cash flow

See full
Operating cash flow-$11.8M-477%
CapEx$1.3K-97.9%
Free cash flow-$11.8M-460%

Valuation

See full
Market cap$157.21M+6.6%
P/S14.5×

Profitability

See full
Gross margin89.3%
Operating margin-250.1%
Net margin-232.2%
FCF margin-280.5%

Returns & leverage

See full
Return on equity-52.4%-5.3pp
Current ratio12.6×-4.5×

Where this comes from

Reported directly by Alpha Cognition in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Alpha Cognition’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alpha Cognition's license — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alpha Cognition's license — revenue?
Alpha Cognition (ACOG) reported license — revenue of $29.98K in Q1 2026.
How has Alpha Cognition's license — revenue changed year-over-year?
Alpha Cognition's license — revenue decreased by 98.8% year-over-year, from $2.58M to $29.98K.
What does license — revenue mean?
This metric represents the total revenue generated from licensing agreements, intellectual property rights, or technology transfer arrangements within the company's biopharmaceutical portfolio. It reflects the commercial success of monetizing proprietary research and development assets through partnerships or third-party collaborations. Monitoring this figure helps investors assess the company's ability to derive value from its pipeline without direct product sales.